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The idea that susceptibility to breast cancer is
determined not only through inherited germline
mutations but also by epigenetic changes induced
by alterations in hormonal environment during fetal
development is gaining increasing support. Using
findings obtained in human and animal studies, this
review addresses the mechanisms that may explain why
daughters of mothers who took synthetic estrogen
diethylstilbestrol (DES) during pregnancy have two times
higher breast cancer risk than women who were not
exposed to it. The mechanisms likely involve epigenetic
alterations, such as increased DNA methylation and
modifications in histones and microRNA expression.
Further, these alterations may target genes that regulate
stem cells and prevent differentiation of their daughter
cells. Recent findings in a preclinical model suggest that
not only are women exposed to DES in utero at an
increased risk of developing breast cancer, but this risk
may extend to their daughters and granddaughters as
well. It is critical, therefore, to determine if the increased
risk is driven by epigenetic alterations in genes that
increase susceptibility to breast cancer and if these
alterations are reversible.DES caused rare reproductive system cancers in youngIn the early 1990s, Drs Barker [1] and Trichopoulos [2]
proposed that the risk of developing cardiovascular
diseases and breast cancer, respectively, might be pro-
grammed during fetal development. According to
Dr Barker, inadequate nutrition during early life and
consequent low birth weight may program some cells in
the fetus to have metabolic characteristics that can lead
to increased cardiovascular disease risk later in life [3].Correspondence: clarkel@georgetown.edu
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2014Dr Trichopoulos and collaborators discovered that high
birth weight and other indicators of exposure to high
hormone levels in utero increase later breast cancer risk
[2]. Both hypotheses have been confirmed in numerous
studies, and it also has been shown that the effects
are independent of adult body weight.
The reason why high birth weight is linked to in-
creased breast cancer risk may be due to elevated preg-
nancy estrogenic environment [4], but also to changes in
leptin, adiponectin, glucose, insulin and insulin-like
growth factor levels. The major difficulty in determining,
for example, if high in utero estrogen levels increase
later breast cancer risk is that data must be available
for both fetal hormonal environment and breast cancer
incidence approximately 50 years later. These data can
be obtained from daughters whose mothers took
the synthetic estrogen diethylstilbestrol (DES) during
pregnancy.
In the early 1940s, physicians started prescribing DES
to pregnant women who exhibited signs of being in dan-
ger of having a miscarriage. The rationale for this prac-
tice was that miscarriage is preceded by a drop in
estrogen levels, and providing women with estrogen
might help to sustain the pregnancy. However, Herbst
and colleagues [5] discovered in the early 1970s that
daughters; therefore, cohorts were established to follow
the offspring of the exposed women. At the present
time five centers in the US are still recruiting women
and men who were exposed to DES in utero for Con-
tinuation of Follow-up of DES-Exposed Cohorts trial
(ClinicalTrials.gov ID NCT00340600).
In this review, findings related to in utero DES expos-
ure and breast cancer are discussed for the purpose of
weighing evidence as to whether fetal hormonal environ-
ment can impact breast cancer risk in women several
decades later. Since causal studies can readily be per-
formed using animal models, findings obtained in DES-l Ltd. The licensee has exclusive rights to distribute this article, in any medium,
is time, the article is available under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Hilakivi-Clarke Breast Cancer Research Page 2 of 102014, 16:208
http://breast-cancer-research.com/content/16/2/208exposed mouse and rat offspring also are discussed. Im-
portantly, animal studies were done prior to any epi-
demiological studies addressing a possible link between
maternal DES exposure and breast cancer risk among
daughters could be performed. By the 1980s, exposed
daughters in the cohorts began to be old enough to de-
velop breast cancer and several human studies have been
performed since to determine if maternal exposure to
DES during pregnancy increases an offspring’s breast
cancer risk.
Maternal exposure to diethylstilbestrol during
pregnancy and breast cancer risk among
daughters
The idea that DES prevents miscarriage was tested in
the 1940s by Smith and Smith [6,7] in a clinical study
and they reported fewer spontaneous abortions, preterm
labor, and pre-eclampsia in women receiving DES during
pregnancy. However, since the controls were not se-
lected randomly and the study was not performed
blindly, both the study design and interpretation of the
data were compromised. It later became apparent that
DES treatment was ineffective at preventing miscarriage
[8] and now it is known that it in fact increases the risk
of miscarriage [9].
The exact number of women who used DES is not
known, but it is estimated to have been between 5 to 10
million women worldwide. These numbers may be an
underestimation, as DES was marketed by several drug
companies and under several different trade names and was
included in some prenatal vitamin preparations. Further, in
1954 DES use was approved for livestock to promote
growth, and two years later approximately two-thirds of US
beef cattle were treated with DES [10]. The US Food and
Drug Administration banned DES in 1971 for pregnant
women and in 1973 for cattle when physicians reported
several cases of clear cell adenocarcinoma of the vagina and
cervix in young women whose mothers took DES [5]. How-
ever, DES use continued in Europe and other parts of the
world after 1971. For example, according to DES Timeline
[11], DES prescriptions continued until 1977 in France,
1980 in Spain, 1981 in Italy and 1983 in Hungary.
Findings in animal studies
Since estrogens are linked to increased breast cancer
risk, and since maternal DES exposure induces cancers
in the offspring’s reproductive tissues, a concern rose
that daughters exposed to DES might exhibit increased
risk of developing breast cancer. Animal studies were
first done to investigate the effect of in utero or neonatal
DES exposure on mammary gland development [12-15]
and later mammary tumorigenesis [16-21]; they are
summarized in Table 1. The amount of DES given to
pregnant mice or rat dams varied from study to study(0.2 to 12,000 μg/day, which translates in rats to ap-
proximately 1 μg/kg to 60 mg/kg DES per day; in preg-
nant women the daily DES dose ranged from 100 μg/kg
to 2 mg/kg), as did the route of administration (subcuta-
neous injection or via feed) and mammary tumor model
used (spontaneous, carcinogen-induced, or ACI rats, which
develop mammary tumors upon estrogen exposure).
The animal studies show that the doses of DES rele-
vant to pregnant women increased later risk of develop-
ing mammary tumors. Specifically, female offspring of
rat dams exposed to a total of 1.2 μg DES either on ges-
tation week 2 or 3 [16], to 0.6 μg or 4 μg DES on both
gestation days 15 and 18 (all via injection) [18,19], or via
diet to 0.1, 1 or 10 ppm DES between gestation days 13
and 21 (week 3) [21] exhibited increased mammary can-
cer risk. An increase in risk also was seen in rats ex-
posed to a single dose of 0.1, 1 or 10 μg or less of DES
at birth [20]. In mice, the effect of neonatal exposure to
DES on mammary gland development has been studied
by many investigators (see below), but not on mammary
tumorigenesis. It is apparent from the rat studies that
high maternal DES doses, especially if they started early
in pregnancy, prevented implantation or caused mis-
carriage [20,21], as is the case in humans [9]. Further, a
postnatal exposure for several consecutive days reduced
mammary tumorigenesis [22], consistent with the data
showing that postnatal exposure (prior to puberty onset)
to estrogens protects against mammary cancer [23].
Effects on mammary glands in animals
In addition to an increase in mammary tumorigenesis in
animal models, high in utero estrogenic environment
impacts the development of the mammary gland, which
begins with the formation of the mammary lines on ges-
tational day 10 in the mouse and rat [24]. Ductal
branching morphogenesis begins on gestational day 16
when epithelial cells from the mammary bud grow down
into the mesenchyme and the mammary fat pad. How-
ever, the growth of the mammary tree remains rather
quiescent until the animal reaches puberty during post-
natal week 4 [25,26]. At puberty, terminal end buds
(TEBs), which are located at the tips of growing epithe-
lial ducts, lead to the growth of the mammary epithelial
tree. As the epithelium grows, bifurcation of TEBs gives
rise to ducts and alveolar buds, which further differen-
tiate to lobules. When TEBs reach the edges of the fat
pad in 8- to 10-week-old mice and rats, they regress to
terminal buds [27]. TEBs give rise to malignant mam-
mary tumors in carcinogen-treated animals [27], and
corresponding structures in the human breast (terminal
ductal lobular unit) appear to be the site of breast cancer
initiation in most women [28]. Further, the number of
TEBs correlates with breast cancer susceptibility [27,29].
After TEBs regress in adult glands, the glands are no
Table 1 Summary of results on mammary gland development and mammary tumorigenesis obtained in mice and rats
exposed to diethylstilbestrol in utero, at birth, during neonatal period (between days 0 and 5) or postnatally






Effect on mammary gland or
mammary cancer
Effects on mammary gland
Nagasawa et al. 1978 [12] Balb/cfC3H
mice
5 μg 0-5 Postnatal 100% no CL Hyperplasia↑
20 μg 0-5 Postnatal 100% no CL
Boylan 1978 [13] Rat 1.2 μg Week 2 G Percentage live deliveries: 97/
F1 94%
Normal
12 μg Week 2 G 50% Normal
60 μg Week 2 G 27% Normal
120 μg Week 2 G 33% Normal
1,200 μg Week 2 G No surviving pups
12,000 μg Week 2 G No surviving pups Normal
1.2 μg Week 3 G 81/F1 78% Slightly enlarged nipples
120 μg Week 3 G 62/F1 57%
12,000 μg Week 3 G No surviving pups
Bern et al. 1987 [14] Balb/c mice 5 × 10-5 μg 0-5 Postnatal Cervicovaginal lesions12%,
65% no CL
HANs 10%
5 × 10-4 μg 0-5 Postnatal 19%, 88% no CL HANs 19%
5 × 10-3 μg 0-5 Postnatal 42%, 95% no CL HANs 41%
5 × 10-2 μg 0-5 Postnatal 63%, 100% no CL HANs 7%
5 × 1 μg 0-5 Postnatal 80%, 100% no CL HANs 12%
Vassilacopoulou and Boylan
1993 [15]




Boylan and Calhoon 1979 [16] Rat/DMBA 1.2 μg Week 2 G Not studied Multiplicity↑
1.2 μg Week 3 G Multiplicity↑
Boylan and Calhoon 1983 [18] Rat/DMBA 0.6 + 0.6 μg 15 + 18 G Not studied Incidence +multiplicity↑
Rothschild et al. 1987 [19] ACI rat 0.4 + 0.4 μg 15 + 18 G Not studied No change
4 + 4 μg 15 + 18 G Incidence↑
Ninomiya et al. 2007 [20] Rat/DMBA 0.1 μg Birth (one dose) Normal cycle, 40% CL Multiplicity↑
1 μg Birth (one dose) 19% PE, 50% CL, U w↓ Incidence +multiplicity↑
10 μg Birth (one dose) 77% PE, 92% CL, U w↓ Multiplicity↑
100 μg Birth (one dose) 100% PE, 100% CL, O + U w↓ No change
Yoshikawa et al. 2008 [22] Rat/DMBA 14 x 1 μg 0-14 Postnatal 100% PE, no CL, O + U w↓, E2
and P↓
Incidence↓
5 x 1 μg 0-5 PE, no CL, O + U w↓, E2 and
P↓
Incidence↓
9 x 1 μg 6-14 PE, no CL, O + U w↓ No change
Kawaguchi et al. 2009 [21] Rat/DMBA 0.1 ppm 0-21 G Few surviving pups
1 ppm 0-21 G No surviving pups
10 ppm 0-21 G No surviving pups (Assessed 10 weeks after
100 ppm 0-21 G No surviving pups DMBA exposure):
0.1 ppm 13-21 G 11% no CL Incidence +multiplicity↑
1 ppm 13-21 G 30% no CL Incidence +multiplicity↑
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Table 1 Summary of results on mammary gland development and mammary tumorigenesis obtained in mice and rats
exposed to diethylstilbestrol in utero, at birth, during neonatal period (between days 0 and 5) or postnatally
(Continued)
10 ppm 13-21 G Very few surviving pups Incidence↑
100 ppm 13-21 G No surviving pups
aIn control mice, corpora lutea (CL) is present in about 31 to 36% of adults, whilst in control rats it is present in 100% of adult animals. DES, diethylstilbestrol;
DMBA, dimethylbenz[a]antracene; E2, estradiol; F1, F1 generation; G, gestation; HAN, hyperplastic alveolar nodule; O, ovary; P, progesterone; PE, persistent estrus;
U, uterus; w, weight.
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cinogens, such as chemicals or radiation [30,31]. Import-
antly, in utero exposure to DES leads to an increase in
TEB numbers [20,32]. It is thus possible that one of the
mechanisms causing an increase in mammary cancer
risk in DES offspring is an increase in the number of tar-
gets for malignant transformation.
Findings in human studies
Several published studies have investigated breast cancer
risk in the daughters of DES mothers, the majority of
which were cohort studies done in the US. As the
women in the cohorts aged, their breast cancer risk grew
higher, compared with matched non-exposed controls
[9,33-36]. The findings clearly indicate that after age
40 years the incidence of breast cancer is at least two-
fold higher in the daughters of DES-exposed mothers.
Many pregnant women in Europe and Australia also
used DES, but the peak exposure occurred 10 to 20 years
later than in the US, and this probably explains why a
recent study done in Europe found a trend but not a sig-
nificant increase in breast cancer risk among them [37].
Once the European daughters reach the age when breast
cancer is more commonly detected, they too are likely to
exhibit a significant increase in breast cancer risk.
Density of TEBs in rodents might be modeling mam-
mographic density in women. Mammographic density is
determined as a ratio between epithelial area containing
the epithelial and stromal/connective tissue cells, and
the whole breast (epithelial area plus adipose cells).
Mammographic density thus reflects the number of epi-
thelial cells, especially terminal ductal lobular units [38],
and it is strongly linked to increased breast cancer risk
[39]. No human studies have been published about in
utero DES exposure and mammographic density. How-
ever, since a surrogate marker of having been exposed to
elevated pregnancy hormonal environment - high birth
weight - is associated with increased mammographic
density [40], it is possible that DES daughters also have
increased mammographic density.
To summarize, animal and human studies have gene-
rated similar findings and indicate that there is a causal
link between maternal exposure to DES during preg-
nancy and increased breast cancer risk among femaleoffspring. According to animal studies, the increase in
risk may reflect the presence of a higher number of
TEBs in the mammary epithelium in the DES offspring.
Baik and colleagues [41] have proposed that the increase
in mammary epithelial cells in in utero estrogen-exposed
females is caused by a high number of mammary stem
cells or an increase in their potential to generate daugh-
ter cells. Our unpublished data support this conclusion
and show that in utero exposure to the synthetic estro-
gen ethinyl estradiol increases the stem-cell like popula-
tion in the developing mammary gland.
Mechanisms mediating the effects of in utero
diethylstilbestrol exposure on the mammary
gland
When determining how maternal exposure to DES dur-
ing pregnancy can impact mammary gland development
and breast cancer risk, several questions need to be an-
swered. First, what are the changes in the fetal mam-
mary gland caused by DES? Second, how are these
changes maintained to adult life? The second point is es-
pecially important, since there is no evidence that
in utero DES exposure would induce mutations in the
mammary tissue [42], or that DES daughters develop
breast cancer at an earlier age than non-exposed daugh-
ters [9,35].
Several signaling factors, expressed in the epithelial
cells and mesenchyma, have been identified that are
critical for fetal mammary gland development [25,26].
Interestingly, although the estrogen receptor (ER) is
expressed in the fetal mammary gland [26,43], findings
obtained in ER knockout mice show that the fetal mam-
mary gland can develop normally without this receptor
[44,45]. This is surprising since in utero or neonatal ex-
posure to estrogens, including DES, alters fetal and neo-
natal mammary gland development in humans [46] and
mice [47]. A likely explanation for these findings is that
although ER is not required for fetal mammary gland de-
velopment, estrogens can modify the developmental
process by regulating or interacting with the signaling
factors that are essential for its development, such as the
Wnt/β-catenin pathway, parathyroid hormone-related
protein, bone morphogenic protein 4 and the insulin-
like growth factor family [48-50].
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transcriptome of the mammary glands in animals exposed
to estrogenic compounds in utero. Umekita and colleagues
[32] investigated the effect of neonatal exposure to DES on
gene expression in the TEBs, using a dose (1 μg/kg) that is
known to increase the number of these structures [20].
The most significant changes in gene expression involved
the NF-kB signaling pathways at puberty onset and ERK
pathways in adult mammary glands [32]. NF-kB is linked
to breast cancer progression [51] and anti-estrogen resis-
tance [52], and among many functions of ERK are those
leading to increased breast cancer risk and impaired
response to anti-estrogens as well as poor prognosis [53].
There is general agreement that the changes in the
transcriptome of adult tissues found to be affected by al-
terations in the in utero environment are likely to have
been epigenetically induced. This is because the epige-
netic signature in all fetal cells, including germ cells, is
established during early development and the signature
then interprets the information in the genetic code that
is inherited from both parents by means that do not
involve a change in DNA sequence [54].
Epigenetic processes mediating the effects of in utero
diethylstilbestrol exposure
Gene expression can be altered as a consequence of
mutations or epigenetic changes. In contrast to gene
mutations within the DNA, epigenetic changes involve
post-transcriptional modifications; that is, methylation
of gene promoter regions, histone modifications, de-
position of certain histone variants along specific gene
sequences and microRNA (miRNA) expression. Al-
though both changes are heritable, an important dis-
tinction between the two is that mutations are not
reversible, but epigenetic modifications generally are.
Probably the most common mechanism of epigenetic
gene silencing is methylation [55], and it might also be
the most important. DNA methyltransferases (DNMTs)
catalyze the methylation of genomic DNA by adding a
methyl group (CH3) onto the 5-carbon of the cytosine
ring within CpG dinucleotides. Histone modifications
are complex, as they involve not just histone methylation
but also acetylation, deacetylation and other post-
translational changes. These modifications occur in the
amino-terminal tails of histones and affect the 'openness'
of the chromatin, which determines whether a gene is
expressed or silenced (for example, acetylation allows
transcription, while deacetylation represses transcrip-
tion) [56,57]. Trimethylation of histone H3 at lysine K27
is catalyzed by the Polycomb group (PcG) protein en-
hancer of Zeste-2 (EZH2) and results in gene silencing
[58,59]. PcG/H3K27me3 interact with DNMTs [60,61],
and together they establish and maintain silencing of
PcG target genes [62]. Over 2,000 different PcG targetgenes have been identified [63] and they include some
tumor suppressor genes. Many of the PcG target genes
regulate cell fate, including apoptosis, proliferation and
stem cell differentiation [64-66]. As discussed in more
detail below, methylation of PcG target genes is linked
to increased breast cancer risk.
DNMTs may be key players in regulating histones and
the entire epigenomic machinery, since DNA methyla-
tion events often precede histone modifications [67].
Upregulation of DNMTs increases the expression of
EZH2 and other polycombs; this may happen by
DNMTs inducing methylation of non-coding miRNAs
that target the polycombs [68].
Epigenetic alterations induced by in utero
diethylstilbestrol exposure
We and others have observed that the expression of
DNMTs is persistently altered in estrogen-regulated tissues
following estrogenic exposures during early life. In utero
exposure to DES is reported to increase the expression of
DNMT1 in the epididymis [69] and uterus [70]. We found
that DNMT1 expression is increased in the mammary
glands of adult rat offspring of dams exposed to ethinyl es-
tradiol during pregnancy [71]. These changes provide a key
regulatory layer to influence gene expression in the mam-
mary gland and perhaps breast tumors of individuals ex-
posed to DES or other estrogenic compounds in utero.
Promoter methylation
In utero DES exposure alters methylation patterns of
several genes in estrogen’s target tissues, including Hox
genes [72,73], c-fox [74], and Nsbp1 [75], but it has not
been studied whether changes in methylation patterns
occur in the mammary gland. We have explored changes
in methylation in the mammary glands of adult rats ex-
posed in utero to the synthetic estrogen ethinyl estradiol
using global sequencing approaches [71]. Among the
genes that exhibited increased promoter methylation
were several PcG target genes, suggesting that a mater-
nal exposure to synthetic estrogens during pregnancy
causes long-lasting changes in the methylation of genes
that regulate cell fate, including stem cell differentiation.
Histone modifications
As an increase in EZH2 expression in the mammary
glands of mice exposed to DES in utero has been re-
ported [76], histone modifications also seem to be influ-
enced by maternal exposure to synthetic estrogens
during pregnancy. Jefferson and colleagues [77] recently
investigated whether upregulation of lactoferrin and sine
oculis homeobox 1 (Six1) in the uterus of adult mice ex-
posed to DES neonatally is caused by histone modifica-
tions. Their data indicate that neonatal DES exposure
induces changes during the early postnatal period in the
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these changes do not last to adulthood. However, alter-
ations in epigenetic marks at the Six1 locus in the uterus
were persistent [77]. Similarly, changes in the methyla-
tion of Nsbp1 [75] and expression of DNMTs [70] in the
uterus of DES-exposed offspring are different in the
early postnatal period compared to adulthood. This
suggests that some epigenetic alterations are further
influenced by factors operating during postnatal deve-
lopment, such as a surge of estrogens and progeste-
rone from the ovaries at puberty onset.
microRNAs
Maternal exposures during pregnancy have been found
to induce persistent changes in miRNA expression in
the offspring. miRNAs are short non-coding single-
stranded RNAs composed of approximately 21 to 22
nucleotides that regulate gene expression by sequence-
specific base-pairing with the 3’ untranslated region
of target mRNAs. miRNA binding induces post-
transcriptional repression of target genes [78], either by
inducing inhibition of protein translation or by inducing
mRNA degradation. Expression of many miRNAs is sup-
pressed by estrogens [79,80]. Although the effects of ma-
ternal DES exposure during pregnancy on miRNA
expression in the offspring have not been investigated, it
is known that many other manipulations, such as mater-
nal low protein diet, alter miRNA patterns among the
offspring [81]. We recently found that in utero exposure
to ethinyl estradiol lowers the expression of many of the
same miRNAs in the adult mammary gland [82] as are
downregulated by E2 in MCF-7 human breast cancer
cells [79]. Since miRNAs can be silenced by methylation
[83,84] or as a result of increased PcG expression [85],
and they target DNMTs, histone deacetylases and poly-
comb genes [86,87], the observed increase in DNMT
expression, histone marks and EZH2 in the in utero
DES-exposed offspring may be a result of epigenetic
silencing of miRNAs that target them.
Epigenetic alterations and breast cancer risk
Methylation of PcG target genes and tumor suppressor
genes in peripheral blood cells, detected years before
diagnosis, is associated with increased breast cancer risk,
particularly in women with a high familial risk [88-90].
Similar changes have been detected in cells collected by
random periareolar fine-needle aspiration from asymp-
tomatic women at high risk for breast cancer [90].
Among the tumor suppressor genes found to be hyper-
methylated in women at high risk, but who are negative
for germline BRCA1 or BRCA2 mutations, are those en-
coding RARB, ER-α, INK4a/ARF, BRCA1, PRA, PRB,
RASSF1A, HIN-1, and CRBP1. Many of these genes also
are PcG target genes. Methylation of many other, 'non-tumor suppressor' PcG target genes also are observed in
cancer [91,92]. It has been estimated that 53% of the
genes hypermethylated in early-stage breast cancer are
known PcG target genes [93]. Since in utero exposure to
synthetic estrogen causes hypermethylation of PcG tar-
get genes [71] and increases mammary cancer risk [94],
in some women at high risk for breast cancer methyla-
tion of these genes may originate from having been ex-
posed to synthetic estrogens during the fetal period.
Several miRNAs are altered in breast tumors in
women, compared with normal tissue [95]. There is
some evidence that changes in the miRNA profile in the
peripheral blood may serve as biomarkers for the pres-
ence of breast cancer [96], and that these changes in
healthy women may predict for an increase in breast
cancer risk [97]. It remains to be determined whether
epigenetic changes, including downregulation of miR-
NAs seen in some women at high risk for breast cancer,
are induced by an exposure to an excessive in utero es-
trogenic environment.The effects of maternal diethylstilbestrol
exposure are not limited to the F1 generation?
Developing germ cells undergo epigenetic erasure when
they, as primordial germ cells, enter into the fetal gonads
around embryonic day 10 to 11 (in mice and rats), and
then undergo gender-specific reprogramming as germ
cells [98]. It is now clear that reprogramming of these
cells is susceptible to modifications caused by changes in
fetal hormonal environment, such as resulting from an
exposure to DES or other endocrine disruptors. Conse-
quently, these exposures can leave a permanent biochem-
ical footprint on the genome of the F1 generation germ
cells, and this change may be inherited by the F2 gener-
ation germ line and several subsequent generations.
Skinner’s group [99] has investigated differences in
methylation patterns in the germ cells of adult male F3
generation offspring of dams exposed during pregnancy
to vinclozolin, a fungicide with anti-androgenic proper-
ties. Their data indicated that 52 promoter regions were
differentially methylated (either hypo- or hypermethy-
lated), compared with controls [99]. The effects of ma-
ternal vinclozolin on germ cells in F3 generation adult
female offspring also have been explored, and 43 differ-
entially methylated genes were identified [100]. Another
study investigated the effect of maternal exposure to di-
oxin during pregnancy on methylation changes in the
germ cells of adult male F3 generation offspring, and
also identified several differentially methylated genes
[101]. In the most recent study, Skinner and colleagues
[102] showed that maternal exposure to vinclozolin dur-
ing pregnancy altered methylation patterns and gene
expression of primordial germ cells in F3 generation
Hilakivi-Clarke Breast Cancer Research Page 7 of 102014, 16:208
http://breast-cancer-research.com/content/16/2/208male fetuses, compared with the F3 generation control
offspring.
We have investigated changes in the methylation pat-
terns of the mammary glands in three generations of fe-
male offspring of rat dams exposed to ethinyl estradiol
or vehicle during pregnancy [71]. A total of 351 genes
were identified that had their promoter region either
hyper- or hypomethylated in the ethinyl estradiol off-
spring, compared with the controls. Mammary tumori-
genesis and the number of TEBs also were increased in
daughters, granddaughters and great granddaughters of
dams exposed to ethinyl estradiol during pregnancy [71].
In addition to changes in histones and DNA methyla-
tion, miRNA expression may be affected in germ cells by
hormonal exposures during early development. Meunier
and colleagues [103] investigated the effects of neonatal
exposure to synthetic estrogen on miRNA expression in
the adult male germ cells, and discovered that miR-29
was upregulated and its target genes DNMT1, DNMT3A
and DNMT3B were all downregulated. Effects on female
germ cells were not studied, but we and others have
found increased DNMT expression in the breast and re-
productive tissues in in utero ethinyl estradiol- or DES-
exposed animals [69-71]. It is possible that male and fe-
male epigenomes respond differently to a synthetic es-
trogen exposure in utero.
Some researchers have begun to investigate whether
the effects of maternal DES exposure during pregnancy








Figure 1 Proposed model to explain an increase in breast cancer risk
granddaughters, of mothers who took diethylstilbestrol during pregn
terminal end bud.there is no evidence that DES granddaughters have cer-
vical and ovarian abnormalities similar to DES daugh-
ters, there is evidence that they may have more
menstrual irregularities and a higher rate of infertility
than non-exposed granddaughters [104]. In addition,
DES granddaughters may have a slightly higher risk of
ovarian cancer [105]. The granddaughters are still too
young to assess whether they might also be at an in-
creased risk of developing breast cancer.
Future directions
Millions of women in the US, Europe and Australia have
been exposed to DES in the womb, and consequently ex-
hibit about a two times higher breast cancer risk than
unexposed women. The increase in risk may not be lim-
ited to the DES-exposed daughters, but could also in-
crease breast cancer risk in granddaughters and great
granddaughters. Such outcome would be consistent with
the findings we obtained in studies using a synthetic es-
trogen ethinyl estradiol (EE2) [71]. If DES has similar ef-
fects to ethinyl estradiol on the transgenerational increase
in breast cancer risk, it is urgent to find ways to stop the
cycle of inheritance, and also prevent breast cancer in
DES-exposed granddaughters and great granddaughters.
To achieve this goal, we need to understand how ma-
ternal DES exposure during pregnancy increases a
daughter’s breast cancer risk. A plausible model is
proposed in Figure 1. It is evident from studies done in
animal models that in utero DES exposure inducesMaternal 
exposure to DES 
during pregnancy
2-fold increase in 
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in daughters, and possibly granddaughters and great
ancy. DES, diethylstilbestrol; TDLU, terminal ductal lobular unit; TEB,
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[69,70,72-75,77] and the breast [76]. DES exposure
might also have induced epigenetic changes in primor-
dial germ cells and consequently germ cells, and further
be detectable in the somatic cells in granddaughters and
great granddaughters. We are not aware of any study
that has compared epigenetic changes in germ cells and
the next generation somatic cells in individuals exposed
to DES or other endocrine disruptors in utero. Second,
we should investigate whether the transgenerational in-
crease in breast cancer risk can be prevented with drugs
that reverse epigenetic modifications. Our preliminary
studies in mice suggest that this is achievable in daugh-
ters by using the well-tolerated and non-toxic histone
deacetylase inhibitor valproic acid and DNMT inhibitor
hydralazine. However, whether these compounds also
prevent an increase in granddaughters and great grand-
daughters in experimental models remains to be investigated.
Conclusions
In summary, women exposed to DES in utero are des-
tined to be at an increased risk of developing breast can-
cer, and this risk may extend to their daughters and
granddaughters as well. It is of critical importance to de-
termine if the increased risk is driven by epigenetic alter-
ations in genes that increase susceptibility to breast
cancer and if these alterations are reversible.
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